Sudair Pharma Company Pharmaceutical Import Profile — Saudi Arabia (DGFT 2022–2026)

Name: Sudair Pharma Company Pharmaceutical Import Records from India — 2 Products, $3.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sudair Pharma Company — Pharmaceutical Importer Profile (2026) | 2 Products, $3.3M Trade | TransData Nexus

Sudair Pharma Company

Pharmaceutical Importer · Saudi Arabia · Diabetes & Endocrine Focus · $3.3M Total Trade · DGFT Verified

Sudair Pharma Company is a pharmaceutical importer based in Saudi Arabia with a total trade value of $3.3M across 2 products in 2 therapeutic categories. Based on 80 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sudair Pharma Company sources from 3 verified Indian suppliers, with Msn Laboratories Private Limited accounting for 96.9% of imports.

Sudair Pharma Company — Import Portfolio & Supplier Network

Sudair Pharma Company import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sudair Pharma Company?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Msn Laboratories Private Limited	$3.2M	100	96.9%
Cipla Limited	$100.0K	14	3.0%
Granules India Limited	$1.4K

What Formulations Does Sudair Pharma Company Import?

Formulation	Value	Ships
Sitagliptin 100MG (50x10 s) sudair	$200.0K	4
Dapagliflozin 10MG 60x10 sudair	$121.0K	3
Apixaban 2.5MG (50x10s)	$117.8K	3
Apixaban 5MG (10x50s)	$100.0K	2
Sitagliptin (juleen) 100MG (60x10's) sudair -sa batch	$61.2K	2
Sitagliptin (juleen) 100MG (60x10's) sudair -sa batch	$57.9K	2
Sitagliptin (juleen) 100MG (60x10's) sudair -sa batch	$57.9K	2
Tiare 90MG (1x10s)	$55.7K	3
Methotrexate spc 2.5 tablets	$50.0K	1
Methotrexate spc 2.5 tablets methotrexate 2.5MG inv.qty.47880 Pack 10x10s=4788000	$50.0K	1
Sitagliptin (juleen) 100MG (60x10's) sudair -sa batch	$50.0K	1
Sitagliptin (juleen) 100MG (60x10's) sudair -sa batch	$50.0K	1
Sitagliptin (juleen) 100MG (60x10's) sudair -sa batch	$50.0K	1
Sitagliptin (juleen) 100MG (60x10's) sudair -sa batch	$50.0K	1
Sitagliptin (juleen) 100MG (60x10's) sudair -sa batch	$50.0K	1

Sudair Pharma Company imports 107 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sitagliptin	Diabetes & Endocrine	$3.2M	78	4.3%	4
2	Methotrexate	Immunosuppressants	$100.0K	2	0.3%	10

Sudair Pharma Company imports 2 pharmaceutical products across 2 categories into Saudi Arabia totaling $3.3M.

Sudair Pharma Company — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sudair Pharmaceutical Company (SPC) is a Saudi-based pharmaceutical manufacturer established in 2014, with its headquarters in Riyadh, Saudi Arabia. The company was founded with the vision of building an advanced pharmaceutical manufacturing complex to combat chronic and life-threatening diseases, aiming to fulfill the unmet needs in the pharmaceutical sector within Saudi Arabia and the MENA region.

SPC owns land in Sudair Industrial City, approximately 100 km north of Riyadh, encompassing more than 77,000 square meters. This site is designated for the construction of manufacturing facilities through joint ventures with major pharmaceutical industry groups. The initial phase focuses on establishing an oncology medicine plant.

In addition to its manufacturing operations, SPC has engaged in strategic partnerships with international pharmaceutical companies, including Qilu Pharma, MSN Laboratories, Granules India, Gero Pharm, Dr. Reddy’s, Accord, and Cipla. These collaborations aim to enhance the company's product portfolio and technological capabilities.

2Distribution Network

SPC's distribution network is primarily centered within Saudi Arabia, focusing on the domestic market to meet the healthcare needs of the region. The company's manufacturing facility in Sudair Industrial City serves as the hub for production and distribution. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, SPC's strategic partnerships with international pharmaceutical companies suggest a robust supply chain designed to ensure the efficient delivery of products across the country.

3Industry Role

SPC operates as a pharmaceutical manufacturer within Saudi Arabia's pharmaceutical supply chain. The company's focus on local production aims to reduce dependency on imported pharmaceutical products, particularly in critical therapeutic areas such as oncology and hematology. By establishing manufacturing facilities within the country, SPC contributes to the localization of advanced pharmaceutical-biologics, enhancing the availability and accessibility of essential medicines to the Saudi population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sudair Pharma Company

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SPC's sourcing strategy exhibits a high concentration, with a total import value from India amounting to $3.3 million USD across 80 shipments. The product portfolio imported from India is limited to two products: Sitagliptin and Methotrexate, which fall under the therapeutic categories of Diabetes & Endocrine and Immunosuppressants, respectively. This narrow focus indicates a strategic choice to concentrate on specific high-demand products, potentially streamlining procurement and inventory management.

The primary supplier, MSN Laboratories Private Limited, accounts for 96.9% of the shipments, suggesting a strong and stable relationship. The secondary supplier, Cipla Limited, contributes 3.0% of the shipments, indicating a supplementary role in the supply chain. The minimal involvement of Granules India Limited (0.0%) suggests limited engagement or a nascent partnership. This supplier concentration could pose risks related to supply chain disruptions; however, the established relationships with reputable suppliers may mitigate such concerns.

2Supply Chain Resilience

SPC's supply chain resilience is influenced by its reliance on a limited number of suppliers for specific products. The company's focus on Sitagliptin and Methotrexate, sourced predominantly from MSN Laboratories Private Limited, indicates a streamlined procurement strategy. While this approach may enhance operational efficiency, it also exposes SPC to potential risks associated with supply chain disruptions, such as production delays or geopolitical issues affecting supplier operations.

Importing Pharmaceuticals into Saudi Arabia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Saudi Arabia

1Regulatory Authority & Framework

The Saudi Food and Drug Authority (SFDA) is the primary regulatory body overseeing pharmaceutical imports and marketing in Saudi Arabia. The SFDA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the country.

Key legislation governing pharmaceutical imports includes the Saudi Food and Drug Authority Law, which outlines the regulatory framework for the import, registration, and distribution of pharmaceutical products. The law emphasizes compliance with international standards and the necessity for obtaining marketing authorization prior to the sale of pharmaceutical products in Saudi Arabia.

The marketing authorization pathway for Indian generics involves several steps:

1. Product Registration: Submission of a comprehensive dossier to the SFDA, including detailed information on the product's composition, manufacturing process, and clinical data.

2. Quality Assessment: Evaluation of the product's quality, safety, and efficacy based on the submitted data.

3. Approval and Licensing: Upon successful assessment, the SFDA grants marketing authorization, allowing the product to be imported and distributed within Saudi Arabia.

This process ensures that all pharmaceutical products, including generics from India, meet the stringent standards set by the SFDA for the Saudi market.

2Import Licensing & GMP

Sudair Pharma Company — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SPC's product strategy focuses on critical therapeutic areas, particularly oncology and hematology, addressing chronic and life-threatening diseases prevalent in Saudi Arabia and the MENA region. By localizing the production of essential medications such as Capecitabine, Abiraterone, Docetaxel, Lenalidomide, Bortezomib, Imatinib, Zoledronic Acid, Azacitidine, and Pemetrexed, SPC aims to enhance the availability and affordability of these treatments.

The market demand for these products is driven by the high incidence of cancer and related disorders in the region. By focusing on these areas, SPC not only meets a critical healthcare need but also positions itself as a key player in the Saudi pharmaceutical industry, contributing to the country's healthcare objectives.

2Sourcing Profile

SPC's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from India, specifically

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Sudair Pharma Company

What products does Sudair Pharma Company import from India?

Sudair Pharma Company imports 2 pharmaceutical products across 2 categories. Top imports: Sitagliptin ($3.2M), Methotrexate ($100.0K).

Who supplies pharmaceuticals to Sudair Pharma Company from India?

Sudair Pharma Company sources from 3 verified Indian suppliers. The primary supplier is Msn Laboratories Private Limited (96.9% of imports, $3.2M).

What is Sudair Pharma Company's total pharmaceutical import value?

Sudair Pharma Company's total pharmaceutical import value from India is $3.3M, based on 80 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sudair Pharma Company focus on?

Sudair Pharma Company imports across 2 categories. The largest: Diabetes & Endocrine (97.0%), Immunosuppressants (3.0%).

Get Full Sudair Pharma Company Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.